Analytical and clinical validation of Alzheimer's disease blood biomarkers with a focus on plasma p‐tau217
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867015890167398400 |
|---|---|
| author | Fernando Gonzalez‐Ortiz Thomas K. Karikari Kaj Blennow |
| author_facet | Fernando Gonzalez‐Ortiz Thomas K. Karikari Kaj Blennow Fernando Gonzalez‐Ortiz Thomas K. Karikari Kaj Blennow |
| collection | Wiley Open Access |
| contents | Analytical and clinical validation of Alzheimer's disease blood biomarkers with a focus on plasma p‐tau217 Fernando Gonzalez‐Ortiz Thomas K. Karikari Kaj Blennow Alzheimer's & Dementia AbstractAlzheimer's disease (AD) represents a growing global health challenge, necessitating accurate and reliable diagnostic methodologies for timely intervention and management. Immunoassays, specifically designed to detect biomarkers associated with AD pathology, have emerged as pivotal tools in diagnostic development. Understanding of the established protocols ensures assay sensitivity, specificity, and reproducibility, thereby enhancing the clinical utility of these diagnostic tools. Here, we explore the considerations in immunoassay development, focusing on phosphorylated tau217 assays.Ultimately, a clear understanding of immunoassay development is paramount in advancing the precision and reliability of AD diagnostics, contributing to early detection, improved patient outcomes, and advancements in therapeutic interventions. 10.1002/alz.13708 http://creativecommons.org/licenses/by-nc/4.0/ |
| doi_str_mv | 10.1002/alz.13708 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_alz_13708 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by-nc/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Analytical and clinical validation of Alzheimer's disease blood biomarkers with a focus on plasma p‐tau217 Fernando Gonzalez‐Ortiz Thomas K. Karikari Kaj Blennow Alzheimer's & Dementia Analytical and clinical validation of Alzheimer's disease blood biomarkers with a focus on plasma p‐tau217 Fernando Gonzalez‐Ortiz Thomas K. Karikari Kaj Blennow Alzheimer's & Dementia AbstractAlzheimer's disease (AD) represents a growing global health challenge, necessitating accurate and reliable diagnostic methodologies for timely intervention and management. Immunoassays, specifically designed to detect biomarkers associated with AD pathology, have emerged as pivotal tools in diagnostic development. Understanding of the established protocols ensures assay sensitivity, specificity, and reproducibility, thereby enhancing the clinical utility of these diagnostic tools. Here, we explore the considerations in immunoassay development, focusing on phosphorylated tau217 assays.Ultimately, a clear understanding of immunoassay development is paramount in advancing the precision and reliability of AD diagnostics, contributing to early detection, improved patient outcomes, and advancements in therapeutic interventions. 10.1002/alz.13708 http://creativecommons.org/licenses/by-nc/4.0/ |
| title | Analytical and clinical validation of Alzheimer's disease blood biomarkers with a focus on plasma p‐tau217 |
| topic | Alzheimer's & Dementia |
| url | https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13708 |